Últimas noticias sobre Pacific Biosciences (NASDAQ:PACB) Bolsa

Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences of California Inc

WIIM

PACB

Pacific Biosciences shares are trading lower after the company issued worse-than-expected preliminary Q4 revenue.

Biotech

News

General

PacBio And Radboud UMC Published Study In American Journal Of Human Genetics

Guidance

Pacific Biosciences Sees Prelim. Q4 Revenue ~$39.2M Vs $40.536M Est.

PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio's groundbreaking Titan-1 platform and PacBio's HiFi sequencing technology. By combining Intus Bio's patented strain-level resolution assay and AI-powered analysis with PacBio's renowned sequencing accuracy, GutID sets a new benchmark in gut microbiome testing, and is the only comprehensive and accurate gut microbiome test available today.

PacBio and Intus Bio Launch GutID: First AI-Powered, HiFi Sequencing Gut Microbiome Test

PacBio Ships First Vega Systems To Berry Genomics For Clinical Assay Development In Asian Markets, With Plans For NMPA Regulatory Approval And Over 50 Additional Units Committed

Ark Invest CEO Cathie Wood is doubling <a href="https://www.benzinga.com/general/biotech">down on genomics</a>.
What Happened: Pacific Biosciences of California Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), known as PacBio, is biotech&#8217;s new kid on the block. The company's Vega sequencer might be the spark that reignites the genomics flame in Ark Invest's portfolios.
ARK Invest has been consistently <a href="https://cathiesark.com/arkk/trades">increasing</a> its stake in PacBio since mid-November. Most recently, the fund added over 24,000 shares on Dec. 3. 
While the stock is down 75% over the past year, Ark's conviction shows no signs of wavering. Wood believes in the sector's long-term growth potential, particularly with genomics merging with AI advancements.
During eToro's &#8220;Digest &amp; Invest&#8221; podcast, Woods emphasized that investors need to look beyond conventional benchmarks. She noted that declining AI training costs enable breakthroughs in gene editing and genome sequencing.
Despite market headwinds like high interest rates, Wood remains bullish, suggesting those ignoring the genomics sector risk missing out on transformative opportunities.
Read Also: <a href="https://www.benzinga.com/news/24/12/42292280/why-purple-biotech-ppbt-stock-is-getting-hammered">Why Purple Biotech (PPBT) Stock Is Getting Hammered</a>
Why It Matters: PacBio carved out its niche in long-read sequencing, an advanced technology that maps entire genomes with unparalleled accuracy. 
The Menlo Park, California-based company's latest launch, the Vega benchtop sequencer, combines affordability ($169,000) with precision. It aims to democratize access to PacBio's HiFi sequencing tech.
PacBio has steadily enhanced its technology, incorporating Sequencing by Binding (SBB) chemistry after acquiring Omniome in 2021. The result? A unique offering that bridges short-read and long-read sequencing needs.
Financially, PacBio is tightening its belt. Non-GAAP operating expenses dropped to $62.4 million in the third quarter 2024, down from $90.9 million a year ago. Meanwhile, consumables sales hit $18.5 million, marking a record for the company's Onso system.
PacBio's story isn't without challenges, considering short interest is over 20%. Yet Wood's Ark holds a 12.26% stake (as of Sept. 30), solidifying her vote of confidence in PacBio.
Biotech's broader market surged by over 29% this year. PacBio&#8217;s shares have struggled, but Wood's accumulation suggests she sees this as a buying opportunity rather than a red flag.
What&#8217;s Next: Vega's launch is slated for early 2025.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42243781/viking-therapeutics-stock-on-brink-of-death-cross-as-weight-loss-hype-loses-momentum">Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum</a></li>
</ul>
Image: Courtesy of Cathie Wood

Long Ideas

Health Care

Tech

Trading Ideas

Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$9.00</td>
<td>$107.2K</td>
<td>9.1K</td>
<td>2.4K</td>
</tr>
<tr>
<td>SRRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$40.00</td>
<td>$29.6K</td>
<td>4.6K</td>
<td>1.1K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$575.00</td>
<td>$36.0K</td>
<td>57</td>
<td>518</td>
</tr>
<tr>
<td>PACB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$5.00</td>
<td>$25.2K</td>
<td>668</td>
<td>405</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$33.00</td>
<td>$31.1K</td>
<td>630</td>
<td>367</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$112.00</td>
<td>$68.8K</td>
<td>260</td>
<td>188</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$960.00</td>
<td>$66.1K</td>
<td>1.8K</td>
<td>177</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$32.50</td>
<td>$37.7K</td>
<td>4.0K</td>
<td>51</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$500.00</td>
<td>$28.0K</td>
<td>103</td>
<td>35</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$60.00</td>
<td>$68.4K</td>
<td>292</td>
<td>12</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we notice a call option trade that happens to be bearish, expiring in 44 day(s) on January 17, 2025. This event was a transfer of 1650 contract(s) at a $9.00 strike. The total cost received by the writing party (or parties) was $107.2K, with a price of $65.0 per contract. There were 9105 open contracts at this strike prior to today, and today 2455 contract(s) were bought and sold. 
• For SRRK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>), we notice a call option sweep that happens to be bullish, expiring in 44 day(s) on January 17, 2025. This event was a transfer of 76 contract(s) at a $40.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $29.6K, with a price of $390.0 per contract. There were 4683 open contracts at this strike prior to today, and today 1199 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bearish sentiment. It expires in 16 day(s) on December 20, 2024. Parties traded 200 contract(s) at a $575.00 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $180.0 per contract. There were 57 open contracts at this strike prior to today, and today 518 contract(s) were bought and sold. 
• For PACB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), we notice a call option trade that happens to be bullish, expiring in 772 day(s) on January 15, 2027. This event was a transfer of 389 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $25.2K, with a price of $65.0 per contract. There were 668 open contracts at this strike prior to today, and today 405 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be bearish, expiring in 79 day(s) on February 21, 2025. This event was a transfer of 62 contract(s) at a $33.00 strike. The total cost received by the writing party (or parties) was $31.1K, with a price of $502.0 per contract. There were 630 open contracts at this strike prior to today, and today 367 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be bullish, expiring in 9 day(s) on December 13, 2024. This event was a transfer of 166 contract(s) at a $112.00 strike. This particular call needed to be split into 37 different trades to become filled. The total cost received by the writing party (or parties) was $68.8K, with a price of $415.0 per contract. There were 260 open contracts at this strike prior to today, and today 188 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 107 day(s) on March 21, 2025. Parties traded 29 contract(s) at a $960.00 strike. The total cost received by the writing party (or parties) was $66.1K, with a price of $2280.0 per contract. There were 1883 open contracts at this strike prior to today, and today 177 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a put option sweep that happens to be bearish, expiring in 107 day(s) on March 21, 2025. This event was a transfer of 51 contract(s) at a $32.50 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $37.7K, with a price of $740.0 per contract. There were 4013 open contracts at this strike prior to today, and today 51 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option trade with bearish sentiment. It expires in 134 day(s) on April 17, 2025. Parties traded 10 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $2800.0 per contract. There were 103 open contracts at this strike prior to today, and today 35 contract(s) were bought and sold. 
• For SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we notice a put option trade that happens to be bearish, expiring in 16 day(s) on December 20, 2024. This event was a transfer of 12 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $68.4K, with a price of $5704.0 per contract. There were 292 open contracts at this strike prior to today, and today 12 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

RXRX

SAVA

SRRK

VRTX

10 Health Care Stocks Whale Activity In Today's Session

UBS analyst John Sourbeer downgrades Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) from Buy to Neutral and announces $2 price target.

Downgrades

Price Target

Analyst Ratings

UBS Downgrades Pacific Biosciences to Neutral, Announces $2 Price Target

Scotiabank analyst Sung Ji Nam maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Sector Outperform and lowers the price target from $7 to $6.

Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $6

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Neutral and raises the price target from $2 to $2.5.

Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2.5

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.2% on Friday.
Shares of Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/SG/earnings">quarterly financial results</a>.
Sweetgreen reported a quarterly loss of 18 cents per share, compared to market expectations for a loss of 16 cents per share. The company reported quarterly sales of $173.400 million which missed the analyst consensus estimate of $175.533 million.
Sweetgreen shares dipped 15% to $35.87 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) shares fell 33.6% to $16.31 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares fell 29% to $1.98 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Maravai LifeSciences Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) declined 26.6% to $5.75 in pre-market trading after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) fell 14.1% to $9.85 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>Pinterest, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) shares dipped 12.7% to $29.62 in pre-market trading after the company reported worse-than-expected third-quarter EPS results.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) dipped 12.6% to $2.14 in pre-market trading after the company reported worse-than-expected third-quarter revenue results.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) declined 9.7% to $119.62 in pre-market trading following third-quarter results.</li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) fell 5.2% to $36.97 in pre-market trading after the company reported worse-than-expected third-quarter revenue results and lowered its FY24 revenue guidance..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

DKNG

MRVI

PINS

RDFN

Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Pacific Biosciences shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Pacific Biosciences Says On The Path To Return To Growth In 2025 And Beyond

Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 37.04 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $39.97 million which missed the analyst consensus estimate of $41.95 million by 4.74 percent. This is a 28.23 percent decrease over sales of $55.69 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Pacific Biosciences Q3 2024 Adj EPS $(0.17) Beats $(0.22) Estimate, Sales $39.97M Miss $41.95M Estimate

Reported Earlier, PacBio's Vega System Expands Accessibility To HiFi Sequencing, Transforming Benchtop Research

PacBio shares are trading higher after the company announced SPRQ sequencing chemistry for its Revio sequencing systems.

PacBio Announces SPRQ Sequencing Chemistry For Its Revio Sequencing Systems

PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program. The 10x Genomics Compatible Partner Program recognizes instruments and workflows compatible with 10x Genomics' products and applications, thereby broadening the range of sequencing solutions available to researchers worldwide.
The Onso platform, designed to provide&nbsp;exceptional&nbsp;accuracy and performance in short-read sequencing, is well-aligned with 10x Genomics' suite of tools for single-cell and spatial biology applications. The Onso platform joins PacBio's MAS-seq long read RNA sequencing solution in the 10x Genomics Compatible Partner Program, as part of PacBio's effort to empower scientists with integrated workflows that enhance insights into genomics and transcriptomics, addressing key challenges in scientific research and advancing discovery in health and disease.

PacBio Onso Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program

U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday.
Shares of Baidu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) fell sharply in today's pre-market trading.
U.S.-listed Chinese stocks traded lower Monday as China's stimulus measures failed to impress the Street.
Baidu shares fell 2.6% to $101.08 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) shares declined 6.6% to $1.85 in pre-market trading after jumping around 28% on Friday.</li>
<li>Genfit S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) shares declined 6.1% to $5.73 in pre-market trading after gaining around 10% on Friday.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares fell 5.2% to $12.23 in pre-market trading.</li>
<li>Melco Resorts &amp; Entertainment Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLCO#NASDAQ">MLCO</a>) shares fell 4.6% to $7.53 in pre-market trading.</li>
<li>Canada Goose Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>) shares fell 4.1% to $11.37 in pre-market trading.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) shares slipped 4% to $8.28 in pre-market trading.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares fell 3.7% to $141.49 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41308141/this-analyst-with-85-accuracy-rate-sees-around-20-upside-in-amd-here-are-5-stock-picks-for-last-week">This Analyst With 85% Accuracy Rate Sees Around 20% Upside In AMD &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

BIDU

GNFT

GOOS

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

TIGR

TSLA

XPEV

Baidu, XPeng And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) rose sharply in <a href="https://www.benzinga.com/quote/LBPH">today's pre-market trading</a>.
Lundbeck agreed to acquire Longboard Pharmaceuticals in a transaction valued at approximately $2.6 billion equity value.
Longboard Pharmaceuticals shares jumped 46.8% to $57.13 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Inventiva S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NYSE">IVA</a>) rose 86.2% to $3.52 in pre-market trading. The company raised up to €348 million to fund Phase 3 NATiV3 clinical trial for MASH, and named new chairman and director.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) gained 92.2% to $0.7297 in pre-market trading. Tevogen Bio announced plans to share $1 billion+ revenue potential of its pipeline portfolio beginning week of Oct. 14.</li>
<li>Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares rose 72% to $4.1100 in pre-market trading after gaining 4% on Friday.</li>
<li>Rani Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares surged 15% to $2.32 in pre-market trading after declining over 12% on Friday.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) gained 15% to $11.50 in pre-market trading.</li>
<li>B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) rose 14.3% to $5.02 in pre-market trading after declining 3% on Friday.</li>
<li>Argo Blockchain plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) shares jumped 12.4% to $1.27 in pre-market trading after gaining around 8% on Friday.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) climbed 9.3% to $1.99 in pre-market trading following a 5% gain on Friday.</li>
<li>Blend Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NASDAQ">BLND</a>) gained 7.7% to $3.92 in pre-market trading after gaining 3% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Molecular Templates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares dipped 76.8% to $0.3401 in pre-market trading as the company's board of directors approved the liquidation and wind-up of the company.</li>
<li>Zapata Computing Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) shares fell 70.7% to $0.0765 in pre-market trading after gaining around 8% on Friday.</li>
<li>Vicinity Motor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) fell 44.1% to $0.0655 in today's pre-market trading. Vicinity Motor failed to renegotiate terms with creditors and concluded workout plan without restructuring.</li>
<li>Notable Labs, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTBL#NASDAQ">NTBL</a>) fell 25.8% to $0.2896 in pre-market trading.</li>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) shares declined 22.4% to $5.54 in pre-market trading after surging 238% on Friday.</li>
<li>Simpple Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) shares declined 18.8% to $0.39 in pre-market trading after gaining 17% on Friday. SIMPPLE, last week, announced new contracts and partnerships in Australia and New Zealand.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 17.1% to $0.8125 in pre-market trading after surging 63% on Friday.</li>
<li>Innovation Beverage Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBG#NASDAQ">IBG</a>) shares fell 15% to $0.8501 after declining 5% on Friday.</li>
<li>BAIYU Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYU#NASDAQ">BYU</a>) declined 13.3% to $0.26 in pre-market trading after declining 35% on Friday.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) fell 6.6% to $1.85 in pre-market trading after jumping around 28% on Friday.</li>
</ul>
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41308141/this-analyst-with-85-accuracy-rate-sees-around-20-upside-in-amd-here-are-5-stock-picks-for-last-week"> This Analyst With 85% Accuracy Rate Sees Around 20% Upside In AMD &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

ARBK

BLND

CERS

DXYZ

LBPH

MTEM

NIVF

NTBL

RANI

RILY

SPPL

TVGN

XPON

ZPTA

Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket

Unusual total active option classes on open include: Getty Images (GETY), Nkarta (NKTX), Truist Financial (TFC), Pac Bio (PACB), Enovix (ENVX), Nov...

Unusually active option classes on open January 7th

PacBio (PACB) has delivered its first Vega systems to Berry Genomics as part of an early access agreement announced in 2022. Under the terms of the...

PacBio announces shipment of Vega systems to Berry Genomics

PacBio (PACB) and Intus Bio unveiled GutID, the first commercial human gut health test powered by Intus Bio's groundbreaking Titan-1 platform and P...

PacBio, Intus Bio collaborate for launch of GutID

Bernstein analyst Eve Burstein maintained a Buy rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $3.00. The c...

Bernstein Sticks to Its Buy Rating for Pacific Biosciences (PACB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pacific Biosciences (PACB – Research Report) and Pharvaris (PHVS ...

Analysts Conflicted on These Healthcare Names: Pacific Biosciences (PACB) and Pharvaris (PHVS)

In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Pacific Biosciences (PACB – Research Report), with a price...

Pacific Biosciences (PACB) Receives a Hold from Morgan Stanley

PacBio announces preliminary Q4 revenue of $39.2M

PacBio (PACB) announced a significant publication from Radboud University Medical Center and its research partners in the American Journal of Human...

PacBio, Radboud UMC announces study results using HiFi long read sequencing

The company also announced preliminary unaudited revenue for the full year 2024 of $154M. "Though challenging, 2024 was a productive year for PacBi...

PacBio reports Q4 preliminary revenue $39.2M, consensus $40.63M

In a report released today, Luke Sergott from Barclays maintained a Hold rating on Pacific Biosciences (PACB – Research Report), with a price targe...

Barclays Reaffirms Their Hold Rating on Pacific Biosciences (PACB)

CRNC

ENVX

GETY

NKTX

NVAX

PHVS

PLUG

TDOC

Press Releases

Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep

PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop

Financing

PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028

PacBio Announces Third Quarter 2024 Financial Results

PacBio to Present at Upcoming Investor Conferences

PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference

PacBio Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay Development for Asian Markets

PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Akoya Biosciences

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

BioLife Solns

ChromaDex

Codexis

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Pacific Biosciences

Noticias

Últimas noticias sobre Pacific Biosciences (NASDAQ:PACB) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL